Cyclic Amyloid-Beta Binding Peptides for Alzheimer's Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, such as anti-Aβ antibodies and cyclic peptides, are ineffective in preventing the formation and proliferation of toxic Aβ oligomers, and there is a lack of diagnostic probes that can specifically bind to Aβ species to enable early detection of the disease.
Innovation Solution
Development of cyclized peptides composed predominantly of D-enantiomeric amino acids with a specific sequence that binds to Aβ species with high affinity, reducing the dissociation constant and enhancing stability, allowing for effective prevention and diagnosis of Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If linear peptides are used to bind Aβ species, then the peptide structure is simpler to manufacture, but the binding affinity and stability are insufficient to prevent oligomer formation
Solution Approach 1:
The patent applies parameter changes by cyclizing the linear peptide structure into a cyclic form. This structural transformation changes the conformational parameters of the peptide, restricting it to a more defined three-dimensional structure that enhances binding affinity to Aβ species while maintaining manufacturability through established cyclic peptide synthesis methods
Solution Approach 2:
The patent employs composite materials by incorporating D-enantiomeric amino acids into the cyclic peptide structure. This creates a chiral composite peptide that exhibits enhanced stability and binding characteristics compared to natural L-enantiomer peptides, combining the benefits of cyclic structure with non-natural amino acid properties
2Reliability
If existing anti-Aβ antibodies and cyclic peptides are used, then some Aβ monomer concentration reduction is achieved, but they cannot prevent the formation and proliferation of toxic Aβ oligomers in established Alzheimer's disease
Solution Approach 1:
The patent applies preliminary action by designing cyclic peptides with pre-optimized high affinity for Aβ oligomers. The cyclic structure is预先 designed to match the conformational epitopes of toxic oligomers, enabling the peptide to bind and prevent oligomer proliferation before they can cause significant damage, rather than merely reducing monomer concentration
Solution Approach 2:
The patent applies local quality by enhancing the binding interface of the cyclic peptide to specifically target Aβ oligomer structures. The peptide sequence is optimized at key binding positions to maximize interaction with oligomer-specific epitopes, providing localized high-affinity binding that prevents oligomer formation more effectively than uniform linear peptides
3Measurement precision
If linear peptides are used for diagnostic probing, then the diagnostic probe is simpler to produce, but the binding affinity and specificity for early detection are insufficient
Solution Approach 1:
The patent applies parameter changes by transforming the linear diagnostic peptide into a cyclic structure with restricted conformational flexibility. This parameter change enhances the peptide's binding specificity and affinity for Aβ oligomers, enabling more sensitive and specific early detection while the cyclic structure remains amenable to synthesis and conjugation with imaging agents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclized peptides demonstrate significantly improved binding affinity and effectiveness in preventing the formation and elimination of toxic Aβ oligomers, and can be used as diagnostic probes for early detection of Alzheimer's, offering a potential therapeutic and diagnostic solution.
Implementation Method 1
the peptide has a linear amino acid sequence that enables it to bind to A-beta, and this property is either retained or enhanced by the linear peptide being in cyclized form by covalent linkage
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to a peptide comprising at least one peptide binding to an amyloid-beta species, wherein the peptide has an amino acid sequence in cyclized form. The use of the peptides in medicine, particularly for the treatment of Alzheimer's disease, is disclosed.